Yahoo Web Search

  1. Sort by

  1. The product will be marketed by GP Pharm, Hemispherx’s commercial partner in Latin America. We believe that rintatolimod is the first drug to receive approval for this indication anywhere...

  2. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic First Product Approved for ME/CFS Indication ...

  3. Hemispherx Biopharma Inc. said Tuesday that it has received approval of a new drug application in Argentina for its treatment for chronic fatigue syndrome. The Philadelphia-based ...

  4. Chronic fatigue syndrome, long a mystery to doctors and researchers, may be linked to bacteria in the gut, a new study finds. Chronic fatigue syndrome ...

  5. Fatigue Market Pipeline 2016 Global Therapeutics Review Report

    PR Newswire via Yahoo FinanceAug 25 03:00 AM

    Profiles discussed in this research are (lofepramine hydrochloride + phenylalanine), alpha-1 proteinase inhibitor (human), BLI-1402, Recombinant A1PI, rintatolimod and Small Molecule for Chronic ...

  6. -Tribune - 08/23/2016 8:34 PM ET Hemispherx Biopharma Inc . said Tuesday that it has received approval of a new drug application in Argentina for its treatment for chronic fatigue< ...

  7. Imagine you are a vibrant healthy child, competing in athletic events and looking forward to a bright future. But suddenly, you catch the flu and life as you know it changes forever.

  8. The product will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America. The approval was based on submission of two pivotal studies, AMP-502 and ...

  9. (NYSEMKT: HEB ) jumps  46%  premarket on increased volume in response to its announcement that lead product candidate Ampligen (rintatolimod) has been approved for sale in Argentina for the ...

  1. Ads
    related to "chronic+fatigue+syndrome"
  1. 123439 results